Literature DB >> 2809160

Failure of hepatitis B immune globulin to protect against exp infection in chimpanzees.

M Wahl1, S Iwarson, P Snoy, R J Gerety.   

Abstract

To study experimentally the protective effect of post-exposure prophylaxis against hepatitis B (HB), a special preparation of hepatitis B immune globulin (HBIG) was injected intravenously (i.v.) into three chimpanzees simultaneously with, or at different time intervals after, intravenous injection of a titred inoculum of hepatitis B virus (HBV). The HBIG was given either simultaneously with the HBV inoculum, at 4 hours after, or at both 4 hours and 4 weeks after the HBV injection. A fourth chimpanzee received a standard preparation of HBIG intramuscularly (i.m.) at both 4 hours and 4 weeks after receiving the HBV injection. A fifth animal received HBIG i.v. 4 hours after the HBV inoculum and at the same time received its first of three HB vaccine injections. All chimpanzees were followed for 1 year. The animals which received HBIG simultaneously with HBV or received HBIG plus vaccine had no serological or biochemical sign of HB during follow-up. The three animals which received HBIG after HBV inoculation all developed HBs-antigenemia and serum aminotransferase (ALT) elevations. HBsAg did however appear in serum several weeks later than expected for the HBV inoculum used. Post-exposure prophylaxis with HBIG did protect the HBV-exposed chimpanzees, only if HBIG was combined with HB-vaccination or if HBIG was given simultaneously with the HBV inoculum.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2809160     DOI: 10.1016/0168-8278(89)90051-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  4 in total

Review 1.  The chimpanzee model for hepatitis B virus infection.

Authors:  Stefan F Wieland
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

2.  Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B.

Authors:  Gonzague Jourdain; Nicole Ngo-Giang-Huong; Linda Harrison; Luc Decker; Woottichai Khamduang; Camlin Tierney; Nicolas Salvadori; Tim R Cressey; Wasna Sirirungsi; Jullapong Achalapong; Prapap Yuthavisuthi; Prateep Kanjanavikai; Orada P Na Ayudhaya; Thitiporn Siriwachirachai; Sinart Prommas; Prapan Sabsanong; Aram Limtrakul; Supang Varadisai; Chaiwat Putiyanun; Pornnapa Suriyachai; Prateung Liampongsabuddhi; Suraphan Sangsawang; Wanmanee Matanasarawut; Sudanee Buranabanjasatean; Pichit Puernngooluerm; Chureeratana Bowonwatanuwong; Thanyawee Puthanakit; Virat Klinbuayaem; Satawat Thongsawat; Sombat Thanprasertsuk; George K Siberry; Diane H Watts; Nahida Chakhtoura; Trudy V Murphy; Noele P Nelson; Raymond T Chung; Stanislas Pol; Nantasak Chotivanich
Journal:  N Engl J Med       Date:  2018-03-08       Impact factor: 91.245

3.  Efficient production of anti-(hepatitis B virus) antibodies and their neutralizing activity in chimpanzees.

Authors:  H Sawada; S Iwasa; O Nishimura; K Kitano
Journal:  Appl Microbiol Biotechnol       Date:  1995-07       Impact factor: 4.813

4.  Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen.

Authors:  N Ogata; L Ostberg; P H Ehrlich; D C Wong; R H Miller; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.